Kidswell Bio Corporation (4584) AI Stock Analysis

• Market Cap: ¥12.14B
• Dividend Yield: N/A
• Average Volume (3M): 946.59K
• Price to Earnings (P/E): 35.8
• Beta (1Y): 1.12
• Revenue Growth: 120.34%
• EPS Growth: N/A
• Country: JP
• Employees: 38
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 3.31
• Shares Outstanding: 49,559,820
• 10 Day Avg. Volume: 1,005,760
• 30 Day Avg. Volume: 946,586
• PEG Ratio: 2.17
• Price to Book (P/B): 3.22
• Price to Sales (P/S): 0.89
• P/FCF Ratio: 4.88
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥249.00
• Price Target Upside: 1.63% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: ¥249.00 ▲(1.63% Upside)

Kidswell Bio Corporation benefits from strong technical momentum; however, its high valuation concerns and persistent profitability issues weigh heavily on its overall performance. Revenue growth and improved cash flow are positive, but financial stability and high leverage remain significant risks.

Kidswell Bio Corporation Business Overview & Revenue Model

Company Description

Kidswell Bio Corporation (4584) is a biotechnology company focused on the development and commercialization of regenerative medicine and biopharmaceutical products. The company operates primarily in the healthcare sector, emphasizing innovative therapies that address unmet medical needs. Its core products and services include the research and development of cell-based therapies and biopharmaceuticals aimed at treating various diseases and medical conditions.

How the Company Makes Money

Kidswell Bio Corporation generates revenue through the development and commercialization of its regenerative medicine and biopharmaceutical products. The company earns money by licensing its technologies, securing partnerships with other healthcare companies for co-development or distribution, and potentially receiving milestone payments and royalties from successful commercialization of its therapies. Additionally, Kidswell Bio may benefit from government grants or research funding aimed at advancing innovative medical treatments.

Kidswell Bio Corporation Financial Statement Overview

Summary

Kidswell Bio Corporation has seen strong revenue growth and improved cash flow, with a positive operating cash flow in 2025. However, persistent profitability challenges and high leverage are significant concerns, reflected in negative net income and high debt-to-equity ratio.

Income Statement

Kidswell Bio Corporation has shown significant revenue growth from 2024 to 2025, with revenues more than doubling. However, the company has consistently struggled with profitability, reflected in negative net income over multiple years. The gross profit margin for 2025 is relatively healthy at approximately 32.2%, but the net profit margin remains negative, indicating ongoing challenges in cost management and efficiency. EBIT and EBITDA margins have improved but remain low, suggesting ongoing operational inefficiencies.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio in 2025, indicating potential leverage risks. However, the equity ratio shows a reasonable portion of assets funded by equity. The return on equity remains negative due to sustained net losses. While the company has improved its cash position, indicating better liquidity management, the overall financial stability remains a concern due to high liabilities and negative equity returns.

Cash Flow

The cash flow statement shows a substantial improvement in operating cash flow, turning positive in 2025, which is a strong indicator of improved cash management. Free cash flow has seen significant growth, moving from negative to positive, reflecting a more efficient use of capital expenditures. However, the free cash flow to net income ratio is skewed by the negative net income, and while operating cash flow has improved, the company still faces challenges in generating consistent profitability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.32B	5.08B	2.43B	2.78B	1.57B	996.54M
Gross Profit	2.01B	1.64B	1.04B	1.53B	1.02B	876.97M
EBITDA	399.96M	116.26M	-1.38B	-620.45M	-531.89M	-983.00M
Net Income	312.68M	-21.14M	-1.42B	-657.43M	-550.86M	-1.00B
Balance Sheet
Total Assets	6.58B	7.01B	5.09B	3.89B	3.47B	3.93B
Cash, Cash Equivalents and Short-Term Investments	2.84B	3.00B	2.23B	1.07B	1.16B	1.46B
Total Debt	1.55B	1.84B	2.58B	1.95B	700.00M	1.10B
Total Liabilities	4.53B	5.60B	4.25B	2.66B	1.77B	2.32B
Stockholders Equity	2.05B	1.41B	831.47M	1.23B	1.70B	1.61B
Cash Flow
Free Cash Flow	0.00	930.26M	-453.63M	-1.42B	-1.17B	-1.27B
Operating Cash Flow	0.00	936.71M	-453.63M	-1.42B	-1.17B	-1.27B
Investing Cash Flow	0.00	65.08M	0.00	-28.82M	526.51M	-22.29M
Financing Cash Flow	0.00	-240.06M	1.62B	1.36B	369.08M	718.35M

Kidswell Bio Corporation Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 245.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4584, the sentiment is Negative. The current price of 245 is below the 20-day moving average (MA) of 259.90, below the 50-day MA of 263.56, and above the 200-day MA of 196.09, indicating a neutral trend. The MACD of -3.25 indicates Positive momentum. The RSI at 43.05 is Neutral, neither overbought nor oversold. The STOCH value of 50.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4584.

Kidswell Bio Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4584	55 Neutral	¥12.14B	35.84	―	―	120.34%	―
4588	53 Neutral	¥19.75B	―	―	―	-9.04%	2.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4583	48 Neutral	¥9.19B	―	―	―	30.92%	26.00%
2370	45 Neutral	¥9.00B	―	―	―	-0.97%	1.19%
4893	41 Neutral	¥6.92B	―	―	―	-96.99%	29.33%
4571	40 Underperform	€14.97B	―	-31.29%	―	51.72%	-34.93%